Cargando…

Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO

INTRODUCTION: Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder primarily affecting children and adolescents. It can lead to chronic pain, bony deformities and fractures. The pathophysiology of CNO is incompletely understood. Scientific evidence suggests dysregulated...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramanan, A. V., Hampson, L. V., Lythgoe, H, Jones, A. P., Hardwick, B, Hind, H, Jacobs, B, Vasileiou, D, Wadsworth, I, Ambrose, N, Davidson, J, Ferguson, P. J., Herlin, T, Kavirayani, A, Killeen, O. G., Compeyrot-Lacassagne, S, Laxer, R. M., Roderick, M, Swart, J. F., Hedrich, C. M., Beresford, M. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550371/
https://www.ncbi.nlm.nih.gov/pubmed/31166977
http://dx.doi.org/10.1371/journal.pone.0215739
_version_ 1783424171694358528
author Ramanan, A. V.
Hampson, L. V.
Lythgoe, H
Jones, A. P.
Hardwick, B
Hind, H
Jacobs, B
Vasileiou, D
Wadsworth, I
Ambrose, N
Davidson, J
Ferguson, P. J.
Herlin, T
Kavirayani, A
Killeen, O. G.
Compeyrot-Lacassagne, S
Laxer, R. M.
Roderick, M
Swart, J. F.
Hedrich, C. M.
Beresford, M. W.
author_facet Ramanan, A. V.
Hampson, L. V.
Lythgoe, H
Jones, A. P.
Hardwick, B
Hind, H
Jacobs, B
Vasileiou, D
Wadsworth, I
Ambrose, N
Davidson, J
Ferguson, P. J.
Herlin, T
Kavirayani, A
Killeen, O. G.
Compeyrot-Lacassagne, S
Laxer, R. M.
Roderick, M
Swart, J. F.
Hedrich, C. M.
Beresford, M. W.
author_sort Ramanan, A. V.
collection PubMed
description INTRODUCTION: Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder primarily affecting children and adolescents. It can lead to chronic pain, bony deformities and fractures. The pathophysiology of CNO is incompletely understood. Scientific evidence suggests dysregulated expression of pro- and anti-inflammatory cytokines to be centrally involved. Currently, treatment is largely based on retrospective observational studies and expert opinion. Treatment usually includes nonsteroidal anti-inflammatory drugs and/or glucocorticoids, followed by a range of drugs in unresponsive cases. While randomised clinical trials are lacking, retrospective and prospective non-controlled studies suggest effectiveness of TNF inhibitors and bisphosphonates. The objective of the Bayesian consensus meeting was to quantify prior expert opinion. METHODS: Twelve international CNO experts were randomly chosen to be invited to a Bayesian prior elicitation meeting. RESULTS: Results showed that a typical new patient treated with pamidronate would have an 84% chance of improvement in their pain score relative to baseline at 26 weeks and an 83% chance on adalimumab. Experts thought there was a 50% chance that a new typical patient would record a pain score of 28mm (pamidronate) to 30mm (adalimumab) or better at 26 weeks. There was a modest trend in prior opinion to indicate an advantage of pamidronate vs adalimumab, with a 68% prior chance that pamidronate is superior to adalimumab by some margin. However, it is clear that there is considerable uncertainty about the precise relative merits of the two treatments. CONCLUSIONS: The rarity of CNO leads to challenges in conducting randomised controlled trials with sufficient power to provide a definitive outcome. We address this using a Bayesian design, and here describe the process and outcome of the elicitation exercise to establish expert prior opinion. This opinion will be tested in the planned prospective CNO study. The process for establishing expert consensus opinion in CNO will be helpful for developing studies in other rare paediatric diseases.
format Online
Article
Text
id pubmed-6550371
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-65503712019-06-17 Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO Ramanan, A. V. Hampson, L. V. Lythgoe, H Jones, A. P. Hardwick, B Hind, H Jacobs, B Vasileiou, D Wadsworth, I Ambrose, N Davidson, J Ferguson, P. J. Herlin, T Kavirayani, A Killeen, O. G. Compeyrot-Lacassagne, S Laxer, R. M. Roderick, M Swart, J. F. Hedrich, C. M. Beresford, M. W. PLoS One Research Article INTRODUCTION: Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder primarily affecting children and adolescents. It can lead to chronic pain, bony deformities and fractures. The pathophysiology of CNO is incompletely understood. Scientific evidence suggests dysregulated expression of pro- and anti-inflammatory cytokines to be centrally involved. Currently, treatment is largely based on retrospective observational studies and expert opinion. Treatment usually includes nonsteroidal anti-inflammatory drugs and/or glucocorticoids, followed by a range of drugs in unresponsive cases. While randomised clinical trials are lacking, retrospective and prospective non-controlled studies suggest effectiveness of TNF inhibitors and bisphosphonates. The objective of the Bayesian consensus meeting was to quantify prior expert opinion. METHODS: Twelve international CNO experts were randomly chosen to be invited to a Bayesian prior elicitation meeting. RESULTS: Results showed that a typical new patient treated with pamidronate would have an 84% chance of improvement in their pain score relative to baseline at 26 weeks and an 83% chance on adalimumab. Experts thought there was a 50% chance that a new typical patient would record a pain score of 28mm (pamidronate) to 30mm (adalimumab) or better at 26 weeks. There was a modest trend in prior opinion to indicate an advantage of pamidronate vs adalimumab, with a 68% prior chance that pamidronate is superior to adalimumab by some margin. However, it is clear that there is considerable uncertainty about the precise relative merits of the two treatments. CONCLUSIONS: The rarity of CNO leads to challenges in conducting randomised controlled trials with sufficient power to provide a definitive outcome. We address this using a Bayesian design, and here describe the process and outcome of the elicitation exercise to establish expert prior opinion. This opinion will be tested in the planned prospective CNO study. The process for establishing expert consensus opinion in CNO will be helpful for developing studies in other rare paediatric diseases. Public Library of Science 2019-06-05 /pmc/articles/PMC6550371/ /pubmed/31166977 http://dx.doi.org/10.1371/journal.pone.0215739 Text en © 2019 Ramanan et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ramanan, A. V.
Hampson, L. V.
Lythgoe, H
Jones, A. P.
Hardwick, B
Hind, H
Jacobs, B
Vasileiou, D
Wadsworth, I
Ambrose, N
Davidson, J
Ferguson, P. J.
Herlin, T
Kavirayani, A
Killeen, O. G.
Compeyrot-Lacassagne, S
Laxer, R. M.
Roderick, M
Swart, J. F.
Hedrich, C. M.
Beresford, M. W.
Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO
title Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO
title_full Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO
title_fullStr Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO
title_full_unstemmed Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO
title_short Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO
title_sort defining consensus opinion to develop randomised controlled trials in rare diseases using bayesian design: an example of a proposed trial of adalimumab versus pamidronate for children with cno/crmo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550371/
https://www.ncbi.nlm.nih.gov/pubmed/31166977
http://dx.doi.org/10.1371/journal.pone.0215739
work_keys_str_mv AT ramananav definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT hampsonlv definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT lythgoeh definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT jonesap definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT hardwickb definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT hindh definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT jacobsb definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT vasileioud definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT wadsworthi definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT ambrosen definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT davidsonj definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT fergusonpj definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT herlint definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT kavirayania definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT killeenog definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT compeyrotlacassagnes definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT laxerrm definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT roderickm definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT swartjf definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT hedrichcm definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo
AT beresfordmw definingconsensusopiniontodeveloprandomisedcontrolledtrialsinrarediseasesusingbayesiandesignanexampleofaproposedtrialofadalimumabversuspamidronateforchildrenwithcnocrmo